Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
95 hedge funds and large institutions have $1.29B invested in Odonate Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 2 closing their positions.
850% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 2
53% more capital invested
Capital invested by funds: $848M → $1.29B (+$446M)
22% more funds holding
Funds holding: 78 → 95 (+17)
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
62% less call options, than puts
Call options by funds: $1.42M | Put options by funds: $3.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.37M |
| 2 |
RI
RTW Investments
New York
|
+$3.72M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.07M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.63M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$7.97M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$6.04M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.56M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$3.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.72M |
ODT Hedge Fund Activity: Q2 2020 in Review
95 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q2 2020, worth a combined $1.29B — up 53% from $848M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ODT positions and 2 closed out — a net gain of 17 holders — while 34 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $4.37M. The largest seller was Carillon Tower Advisers, cutting an estimated $7.97M.
- 95 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q2 2020, up from 78 in Q1 2020.
- Funds reported $1.29B of Odonate Therapeutics, Inc. Common Stock stock for Q2 2020, up 53% quarter-over-quarter.
- 19 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q2 2020 and 2 closed out, a net change of +17 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $4.37M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q2 2020 was Carillon Tower Advisers, an estimated $7.97M sold.
Based on aggregated 13F filings for Q2 2020.